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MinireviewClearing the Brain’s
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levels seem not to be elevated), and coexpression of
APP with each of the human ApoE isoforms causes no
detectable change in cellular A generation. Instead,
Dennis J. Selkoe1
Center for Neurologic Diseases
Harvard Medical School
human neuropathological analyses and mouse model-Brigham and Women’s Hospital
ing suggest that inheritance of ApoE4 leads to a rise inBoston, Massachusetts 02115
the steady state levels of A in the brain, presumably
by enhancing its fibrillogenic potential and/or decreas-
ing its clearance from the brain’s extracellular space.
While the precise mechanism is unclear, it is likely thatElevated cerebral levels of amyloid -protein occur
ApoE4-mediated rises in brain A levels represent auniversally in Alzheimer’s disease, yet only a few pa-
clearance failure. This review will now focus on anothertients show evidence of increased A production.
potential basis for A accumulation—defects in prote-Therefore, defects in proteases that degrade A could
ases that normally degrade the peptide shortly after itsunderlie some or many cases of familial and sporadic
production.AD. This previously neglected topic has begun receiv-
Neprilysin and Insulin-Degrading Enzyme:ing serious attention. Understanding how proteolysis
Two Candidates for Regulators of Aregulates A levels in the cerebral cortex has implica-
Levels in Human Braintions for both the pathogenesis and the treatment of
Metabolic labeling studies in living mice show that newlythis protean disorder.
generated A is very rapidly turned over in the brain
(Savage et al., 1998), suggesting that A-degrading pro-By now, many in the scientific community have warmed
teases help regulate its levels. There are numerous pro-to the hypothesis that the accumulation of thin filaments
teases in the brain that could potentially participate inof the amyloid -protein (A) in limbic and association
A turnover, and the goal of finding a single, dominantcortices constitutes a major threat to neuronal function.
protease that is responsible for the majority of A degra-Although the amyloid hypothesis (more correctly, the
dation may be elusive. Indeed, there is already evidenceA hypothesis) for the causation of Alzheimer’s disease
that several enzymes may contribute to the degradation(AD) still stirs strong passions, the number of genetic,
of A peptides in brain tissue (Table 1). At the outset,biochemical, and animal modeling studies supporting
one must distinguish between proteases that appear toits validity is impressive and growing apace. But proof
degrade A only in its monomeric state and those thatcan only come from successful trials of A-lowering
can degrade oligomeric and/or highly aggregated (fibril-therapies in humans. Happily, this process has recently
lar) forms of the peptide. Very few examples of the latterbegun.
class have been documented, perhaps because the AAlthough a concept that seemed simplistic and far-
peptide becomes resistant to an array of proteases asfetched just 15 years ago has now entered the clinic, we
a result of structural changes associated with its poly-are left with many unresolved and fascinating biological
merization into amyloid fibrils. Among the former class,questions about how a small hydrophobic peptide accu-
two proteases, neprilysin and insulin-degrading enzymemulates in the brain and then apparently initiates cytopa-
(IDE), have received the most attention to date.thology. Perhaps foremost among these is exactly why
Both of these candidate proteases were first chosencerebral A levels are elevated in patients with the dis-
to be tested on synthetic A by laboratories alreadyease. While the field has focused enormous attention
interested in their ability to degrade other peptides
on the complex mechanisms of A production, including
(Howell et al., 1995; Kurochkin and Goto, 1994). But in
the role of the - and -secretases which generate A
the case of IDE, evidence that it could degrade naturally
from its precursor protein (APP), increases in production secreted A also arose independently from an unbiased
currently explain a small minority of cases, specifically screen of cultured cell lines for A-degrading proteases
those bearing inherited mutations in APP or in prese- (Qiu et al., 1998). The principal such activity turned out,
nilins 1 or 2. This realization leaves open the likelihood upon partial purification and inhibitor characterization,
that many, perhaps most, cases of AD are caused by to be an 110 kDa thiol metalloendopeptidase indistin-
faulty clearance of a peptide that is produced at normal guishable from IDE. IDE had previously been shown to
levels throughout life. The mechanisms of A degrada- degrade insulin, glucagon, atrial naturetic peptide (ANF),
tion and clearance have received remarkably little atten- and TGF-, among other small peptides of diverse se-
tion, but that has begun to change, prompting this quence. The recent addition of amylin to this list (Bennett
review. et al., 2000) has furthered the hypothesis that IDE has
Support for the concept that decreased clearance of little sequence specificity but recognizes a conformation
A can actually precipitate the AD phenotype came first that is prone to conversion to a -pleated sheet struc-
from studies of how the inheritance of one or two alleles ture. Such a property could explain its propensity to
of apolipoprotein E4 predisposes one to the disease. degrade several peptides that undergo concentration-
Humans bearing ApoE4 alleles show no evidence of a dependent formation of amyloid fibrils (e.g., insulin, ANF,
general increase in A production (for example, plasma amylin, calcitonin, and A). Importantly, IDE has been
found to degrade rat and human amylin peptides simi-
larly, despite the fact that only the latter can form amy-1 Correspondence: selkoe@cnd.bwh.harvard.edu
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Table 1. Some Proteases Capable of Degrading A
Some Substrates Principal
Protease Class (besides A) Subcellular Loci Recent Findings Relevant to a Role in A Degradation
Insulin-degrading metallo insulin, glucagon, cytosol, peroxisomes, • secreted by microglia
enzyme ANF, TGF-, extracellular fluid, • present on internal membranes at sites of A generation
(insulysin) -endorphin, plasma membrane, • gene located near putative FAD locus
amylin internal membranes
Neprilysin (NEP) metallo endorphins, plasma membrane, • capable of degrading membrane-associated A
enkephalins internal membranes • deletion causes rise in cerebral A levels in vivo
Plasmin serine fibrin, other matrix extracellular fluid • can degrade both monomeric A and fibrils in vitro
proteins
uPA/tPA serine plasminogin extracellular fluid • can be activated by A aggregates to generate plasmin
• uPA gene located near putative FAD locus
Endothelin converting metallo big endothelins, plasma membrane,
enzyme-1 bradykinin, sub- internal membranes
stance P, oxidized
insulin B chain
Matrix metallo Collagen, elastin, extracellular fluid • latent form of MMP-9 accumulates in AD brain
metalloproteinase-9 laminin, pro-TNF
loid fibrils. It appears, therefore, that the motif recog- at 30 min. Importantly, SDS was required to extract A
immediately after its in vivo injection and at all timenized by IDE is not the -pleated sheet region per se
but a conformation of the monomer in a pre-amyloid points thereafter; no peptide was recovered without this
detergent. The authors surmised that the peptide rapidlystate (Bennett et al., 2000).
One concern about the physiological relevance of entered an insoluble phase, probably representing mem-
brane association, before proteolysis occurred. This in-IDE’s ability to degrade secreted peptides such as insu-
lin and A has been that the enzyme occurs principally terpretation is consistent with the conclusion, based on
preinjecting different protease inhibitors, that neprilysinin a soluble form in the cytoplasm. However, a form
of IDE can be labeled on the cell surface, including in produced the A10-37 intermediate, since neprilysin is a
member of the neutral endopeptidase family of mem-neurons, and is also present on intracellular membranes
(Vekrellis et al., 2000). Its mode of entry into membranes brane-anchored proteases found on the cell surface.
Subsequent work provided important evidence that theand the nature of its membrane anchor need to be re-
solved, as IDE does not have a known signal peptide steady state levels of endogenous A are elevated in
the brains of young neprilysin-deficient mice (Iwata etor transmembrane domain. Nevertheless, the existence
of a membrane-anchored form of the protease suggests al., 2001). The rise, while highly significant, was not large,
and plaque formation was not observed. Given the rapidthat it could help regulate insulin signaling at the plasma
membrane and could also participate in the degradation turnover of A in the brain (Savage et al., 1998), if nepri-
lysin were the major degrader of A, its deletion shouldof both soluble and membrane-associated forms of A.
The cleavage products of A produced by IDE are not produce an even greater accumulation. Therefore, other
proteases, including additional members of the neutralneurotoxic and not prone to depositing on amyloid
plaques, and therefore recombinant IDE reduces A tox- endopeptidase family, may compensate in part for the
loss of neprilysin. Indeed, chronic thiorphan infusion,icity in cortical neuronal cultures (Mukherjee et al., 2000).
While endogenous IDE has been specifically shown to which should inhibit several proteases, led to actual
plaque formation in rats (Iwata et al., 2000), a moredegrade synthetic A monomers in homogenates and
membrane fractions of human brain (Perez et al., 2000; robust effect than that of deleting just neprilysin.
An interpretation that could explain the existing dataK. Vekrellis and D.J.S., unpublished data), confirmation
of the effects of this protease in vivo, e.g., in mice lacking on both IDE and neprilysin is that IDE mediates much
of the degradation of soluble, monomeric A but hasthe IDE gene, is now required.
The intracerebral injection of synthetic A peptides less ability to degrade A once it becomes insoluble
and/or oligomeric, whereas neprilysin has little role inin the presence or absence of various protease inhibitors
provided evidence that neprilysin is a major A42-degrad- degrading soluble A but can degrade buffer-insoluble,
SDS-extractable A associated with membranes. Con-ing protease in rat brain, although the enzyme did not
mediate A40 degradation in this paradigm (Iwata et al., sistent with this hypothesis are three additional findings.
First, naturally occurring oligomers (dimers and trimers)2000). The approach involved microinjecting a 250 M
solution of radiolabeled A1-42 into the hippocampi of of secreted A in culture medium are resistant to IDE,
while A monomers in the same sample are avidly de-2-month-old rats, waiting 0–30 min, extracting the iso-
lated hippocampi in 0.1% SDS buffer, and visualizing graded by the enzyme (Qiu et al., 1998; Vekrellis et al.,
2000). Second, IDE occurs abundantly in a soluble, ex-the catabolic products by reverse-phase HPLC. The in-
jected peptide underwent degradation with a half-life tracellular form in the nervous system (as documented
in human CSF and neuronal and microglial culture mediaof 15–20 min, and a single major peak representing a
catabolic intermediate of residues 10–37 was obtained [Qiu et al., 1998; Vekrellis et al., 2000]) in addition to a
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membrane-anchored form, whereas neprilysin occurs As candidate enzymes that degrade A in the brain
are confirmed, it will become important to identify otheralmost exclusively in a membrane-anchored form. And
third, degradation of A in the soluble fraction of brain proteases that activate them and proteins that normally
inhibit them, as these regulatory molecules representappears not to be decreased by inhibition or deletion
of neprilysin (Iwata et al., 2000), whereas degradation attractive therapeutic targets. In this regard, the metal-
loendopeptidase 24.15 has been reported to indirectlyof A in the membrane fraction of brain is decreased
25%–35% by neprilysin inhibitors and 70% by IDE regulate A degradation. Whereas this enzyme does not
proteolyze synthetic A, decreasing its activity (e.g., viainhibitors (K. Vekrellis and D.J.S., unpublished data). In
summary, both neprilysin and IDE may contribute to antisense treatment) leads to increased A levels in cell
culture (Yamin et al., 1999). It is thus possible thatoverall A degradation in the brain, but each may play
a role in distinct subcellular loci and with different forms MP24.15 processes a zymogen of an A protease or
degrades its endogenous inhibitor. Evidence that en-of A. The possibility that different proteases principally
degrade different pools of A in the brain will need to hancing the cerebral levels of a protease inhibitor can
increase A deposition in vivo comes from recent stud-be borne in mind as additional enzymes are evaluated.
Other Candidate A-Degrading Proteases ies of the effects of the serine protease inhibitor, 1-
antichymotrypsin, in APP transgenic mice (Mucke et al.,The plasmin proteolytic cascade, known to be crucial
for fibrinolysis and cell migration, has recently been im- 2000; Nilsson et al., 2001).
A potential clearance mechanism for A aggregates isplicated in A clearance as well. In this cascade, either
of two activators of plasmin, tissue-type plasminogen the phagocytosis of amyloid fibrils by cerebral microglia
and their subsequent degradation by acid hydrolasesactivator (tPA) or urokinase-type plasminogen activator
(uPA), can be posttranslationally activated by binding in late endosomes and lysosomes. While a contribution
by this route is possible, microaggregates of syntheticto fibrin aggregates and then cleave plasminogen to
yield the active serine protease, plasmin, which proteo- A42 shown to be internalized by cultured microglia and
transported to lysosomes were remarkably stable andlyzes fibrin and other substrates. In vitro studies have
suggested that A aggregates can substitute for fibrin were degraded very slowly, leading to their severe accu-
mulation inside cells (Paresce et al., 1997). Therefore, itaggregates in activating tPA. In the nervous system,
plasminogen, tPA and uPA are expressed in neurons, is unclear whether attempted A removal by this route
is beneficial or rather induces a microglial-associatedand tPA is also synthesized by microglia. Experiments
in primary neuronal cultures show that pure plasmin inflammatory response. Of related interest is the current
debate as to whether the dramatic A-clearing effects(at 10–30 nM) can significantly decrease the amount of
neuronal injury induced by aggregated A (16–30 uM) of active and passive A immunization are due to the
clearance of A-antibody complexes by local microglial(Tucker et al., 2000). In vitro biochemical assays indicate
that pure plasmin can proteolyze fibrillar A, although (Bard et al., 2000) and/or the transport of such com-
plexes out of the brain and into CSF and blood (De-at an efficiency about 100-fold less than that for freshly
dissolved (i.e., largely monomeric) A. While these re- Mattos et al., 2001).
Searching for Genetic Evidence of a Primary Defectsults make plasmin the first physiologically relevant pro-
tease shown to degrade aggregated A in vitro, the in A Degradation in Alzheimer’s Disease
Taken together, the biochemical studies in neuronal cul-reaction was about 20-fold less efficient than that involv-
ing aggregated fibrin (Tucker et al., 2000). Moreover, tures, mice, and human brain tissue reviewed above
suggest that specific neural proteases actively degradethis in vitro effect may not predict similar activity on
amyloid fibrils in vivo, because serum amyloid P compo- A monomers under physiological conditions. There-
fore, inherited or acquired defects in A-degrading pro-nent, which is associated with amyloid deposits in AD
brain, is able to bind to and prevent the proteolysis of teases could chronically elevate A levels in a manner
mechanistically distinct from but quantitatively similarisolated cerebral amyloid (Tennent et al., 1995). Evi-
dence for a role of plasmin in regulating A monomer to presenilin mutations. In attempts to date to implicate
A proteases in familial AD, early work is pointing to IDEor polymer levels in vivo has not yet appeared.
Another protease expressed in brain that has been and uPA as candidate genes. Both genes are located on
chromosome 10q, and different sets of late-onset ADevaluated for its ability to degrade A is endothelin con-
verting enzyme-1 (ECE-1) (Eckman et al., 2001). This pedigrees have shown linkage to DNA markers in the
vicinity of these genes. In the NIMH registry of 435 fami-integral membrane zinc metalloprotease, with its active
site located in the lumen and extracellularly, can cleave lies with late-onset AD, genetic linkage to markers near
10q23–q25 as well as allelic association of one of thesethe endothelin precursors and several other biologically
active peptides, including bradykinin, substance P, and markers with AD have been documented. (See accom-
panying minireview by Tanzi and Bertram for more de-the oxidized insulin B chain. Cellular overexpression of
ECE-1 leads to a marked reduction in the levels of natu- tails and references therein [this issue of Neuron].) IDE
is located within the linkage region. However, any asso-rally secreted A40 and A42 peptides in Chinese ham-
ster ovary cells. The purified enzyme directly proteolyzes ciation of the AD phenotype with polymorphisms in the
IDE gene itself remains to be examined. It is of relatedboth synthetic peptides in vitro (Eckman et al., 2001).
Whether this protease can alter A levels in vivo remains interest that missense mutations in IDE which decrease
its ability to degrade insulin in muscle have been discov-to be determined. Other purified proteases that have
been reported to digest synthetic A peptides under ered in the inbred GK diabetic rat, a compelling model
of type 2 diabetes mellitus (Fakhrai-Rad et al., 2000).in vitro conditions include matrix metalloproteinase-9
(Backstrom et al., 1996) and cathepsin D (McDermott In separate experiments, an apparently distinct link-
age region has been localized to chromosome10q,and Gibson, 1996).
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ron].) Work is also underway to search for evidence of Howell, S., Nalbantoglu, J., and Crine, P. (1995). Peptides 16,
linkage between AD and markers on chromosome 3, 647–652.
where the neprilysin gene is found. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Ho-
New Directions in Elucidating A Degradation soki, E., Kawashima-Morishima, M., Lee, H.J., Hama, E., Sekine-
Aizawa, Y., and Saido, T.C. (2000). Nat. Med. 6, 143–150.As the mechanisms of A degradation receive increas-
ing attention, it is important that we design experiments Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P.,
Gerard, C., Hama, E., Lee, H.J., and Saido, T.C. (2001). Science 292,which will yield physiologically and pathologically rele-
1550–1552.vant information. Biochemical experiments in which pu-
Kurochkin, I.V., and Goto, S. (1994). FEBS Lett. 345, 33–37.rified proteases are tested on synthetic A peptides are
McDermott, J.R., and Gibson, A.M. (1996). Neuroreport 7, 2163–becoming of limited interest. The ability of a particular
2166.protease to degrade naturally produced A species at
Mucke, L., Yu, G.Q., McConlogue, L., Rockenstein, E.M., Abraham,physiological concentrations of enzyme and substrate
C.R., and Masliah, E. (2000). Am. J. Pathol. 157, 2003–2010.is paramount. While important clues can be obtained
Mukherjee, A., Song, E., Kihiko-Ehmann, M., Goodman, J.P., Jr.,from cell culture studies, particularly with primary neu-
Pyrek, J.S., Estus, S., and Hersh, L.B. (2000). J. Neurosci. 20, 8745–
rons, this work should be extended increasingly to in 8749.
vivo systems. Each candidate protease will need to be Nilsson, L.N., Bales, K.R., DiCarlo, G., Gordon, M.N., Morgan, D.,
tested in gene-deleted mice to determine its effects on Paul, S.M., and Potter, H. (2001). J. Neurosci. 21, 1444–1451.
normal A economy, as has already been successfully Paresce, D.M., Chung, H., and Maxfield, F.R. (1997). J. Biol. Chem.
done for neprilysin (Iwata et al., 2001). Such knockout 272, 29390–29397.
lines as well as mice transgenic for a protease of interest Perez, A., Morelli, L., Cresto, J.C., and Castano, E.M. (2000). Neuro-
should be bred to APP-overexpressing mice to discern chem. Res. 25, 247–255.
any quantitative effects on cerebral A deposits and Qiu, W.Q., Walsh, D.M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M.,
Rosner, M.R., Safavi, A., Hersh, L.B., and Selkoe, D.J. (1998). J. Biol.their associated glial and neuronal cytopathology. Hu-
Chem. 273, 32730–32738.man brain tissue should also be studied, taking into
Savage, M.J., Trusko, S.P., Howland, D.S., Pinsker, L.R., Mistretta,account in which subcellular locus and under which
S., Reaume, A.G., Greenberg, B.D., Siman, R., and Scott, R.W.conditions (pH, etc) a protease is expected to encounter
(1998). J. Neurosci. 18, 1743–1752.and cleave A.
Tanzi, R., and Bertram, L. (2001). Neuron 32, this issue, 181–184.Given the large percentage of familial AD cases that
Tennent, G.A., Lovat, L.B., and Pepys, M.B. (1995). Proc. Natl. Acad.are not currently explained by abnormalities of A pro-
Sci. USA 92, 4299–4303.
duction, efforts to rule in or out candidate A-degrading
Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi,proteases in genetic studies of AD pedigrees are crucial.
T., Price, D., Walker, D., Scheff, S., McGillis, J.P., Rydel, R.E., and
Depending on the outcome of such work, searches for Estus, S. (2000). J. Neurosci. 20, 3937–3946.
mutations, AD-promoting polymorphisms, or other gene Vekrellis, K., Ye, Z., Qiu, W.Q., Walsh, D., Hartley, D., Chesneau, V.,
defects should also be conducted in so-called “spo- Rosner, M.R., and Selkoe, D.J. (2000). J. Neurosci. 20, 1657–1665.
radic” forms of the disease. And as soon as a candidate Yamin, R., Malgeri, E.G., Sloane, J.A., McGraw, W.T., and Abraham,
protease or its activator(s) or inhibitor(s) are implicated C.R. (1999). J. Biol. Chem. 274, 18777–18784.
genetically, new animal models which reproduce the
genotype and potentially the phenotype of the defect
should be developed. Such studies may reveal in rela-
tively short order whether inherited abnormalities of A
degradation contribute to the genesis of AD. But even if
none are found, pharmacologically upregulating certain
A-degrading proteases or, more plausibly, interfering
with the production or processing of their natural inhibi-
tors could have great therapeutic potential. Time will
tell whether AD represents, at least in part, a clearance
disease.
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